United States Patent 7,776,358 (Venlafaxine Besylate Extended-Release Tablet): Scope, Claim Architecture, and Landscape
United States Drug Patent 7,776,358 is directed to a specific extended-release (ER) venlafaxine besylate tablet defined by (i) a high drug-load tablet core, (ii) a coating system dominated by an ammonio methacrylate copolymer with defined ammonio methacrylate-unit composition, and (iii) defined dissolution performance across a two-medium schedule (SGF then SIF). The claims are structured as a layered narrowing funnel: independent claim 1 covers the general ER tablet with a core drug fraction and coating weight fraction, while dependent claims progressively lock in drug load, copolymer composition, coating level windows, excipient-free limitations, optional matrix/excipient packages, and a numerical dissolution profile.
What is the core claim scope of US 7,776,358?
Independent claim 1: base technical “center of gravity”
Claim 1 defines an ER coated tablet comprising:
- Tablet core
- contains at least 70% venlafaxine besylate (by claim language, core comprises at least 70% venlafaxine besylate)
- Coating over the core
- coating comprises an ammonio methacrylate copolymer component
- coating amount is 3% to 25% of tablet-core weight
The independent claim therefore turns primarily on:
- Very high drug loading in the core (>=70% venlafaxine besylate), and
- Coating weight fraction (3% to 25% relative to core), with
- Ammonio methacrylate copolymer as the dominant coating component (fully defined in dependent claims).
Claim 2 to claim 3: drug-load narrowing
- Claim 2: core comprises 75% to 99% venlafaxine besylate
- Claim 3: core comprises 80% to 95% venlafaxine besylate
These claims create a practical infringement boundary for formulations that might otherwise fall inside claim 1’s >=70% but outside higher drug-load windows.
Claim 4 to claim 8: coating polymer dominance and monomer-unit specification
- Claim 4: ammonio methacrylate copolymer component is at least 50% of coating
- Claim 5: copolymer has 7 mol % to 14 mol % ammonio methacrylate units
- Claim 6: copolymer has 8 mol % to 12 mol % ammonio methacrylate units
- Claim 7: copolymer comprises
- 65% to 100% Type A ammonio methacrylate copolymer
- 0% to 35% Type B ammonio methacrylate copolymer
- Claim 8: further narrows Type mix to
- 85% to 100% Type A
- 0% to 15% Type B
This is the tightest chemical scope in the set. Any design-around that swaps the polymer family, reduces polymer fraction below 50% of coating, or shifts the ammonio methacrylate unit level or Type A/Type B balance can fall outside these dependent claim features even if claim 1 remains broadly met.
Claims 9 to 12: “core free from extended release matrix excipients” + drug amount + coating window
- Claim 9: tablet core is free from extended release matrix excipients
- Claim 10: core further comprises a lubricant and optionally a filler selected from:
- sugars, microcrystalline cellulose, calcium phosphates, mixtures
- Claim 11: core contains 150 to 300 mg venlafaxine besylate
- Claim 12: locks in a multi-parameter subset:
- coating amount 5% to 15% of core weight
- copolymer at least 50% of coating
- copolymer is 85% to 100% Type A and 0% to 15% Type B
Claims 9-12 introduce two additional “gates”:
- No ER matrix excipients in the core (this can be used to distinguish from matrix-type ER approaches), and
- a specific drug mass range (150-300 mg) tied to the defined core/drug loading architecture.
Claims 13 to 17: alternative subset that adds an ER matrix material
Claims 13 to 17 expand the claim family to core embodiments that include a matrix material, with explicit identification of co-processed excipients.
- Claim 13: core further comprises a matrix material
- Claim 14: matrix material is a lipophilic matrix material
- Claim 15: matrix material is co-processed calcium phosphate and fatty acid wax in a ratio:
- 85:15 to 65:35 (calcium phosphate : fatty acid wax)
- Claim 16: core comprises:
- 10% to 20% of the co-processed calcium phosphate/fatty acid wax excipient
- 0.2% to 2% lubricant
- Claim 17: adds coating/polymer constraints to the matrix embodiment:
- coating amount 5% to 25% of core weight
- copolymer at least 50% of coating
- copolymer is 70% to 100% Type A and 30% to 0% Type B
Notably, claim 9 disclaims ER matrix excipients, while claims 13-17 explicitly add a matrix material. In practice, these are alternative claim paths, not necessarily inconsistent, depending on how “extended release matrix excipients” is interpreted versus “matrix material” in the particular claim drafting.
Claim 19: numerical dissolution profile tied to USP apparatus and media schedule
- Claim 19 requires that the tablet exhibits a dissolution profile meeting the following constraints in USP Apparatus 2:
- SGF, pH 1.2
- hours 0 to 2
- then SIF, pH 6.8
- hours 2 to 24
And dissolution targets for venlafaxine at specific time points:
- 2 hours: <30%
- 4 hours: 30% to 55%
- 8 hours: 55% to 80%
- 12 hours: 65% to 90%
- 24 hours: >80%
Claim 19 is a high-value functional constraint. It provides a way to differentiate formulations even if the compositional parameters are similar, because it is anchored to measurable release behavior under a specific pH transition.
How tight is the claim funnel across the set?
The claim set operates as a multi-dimensional narrowing framework:
Core composition gates
- Independent: >=70% venlafaxine besylate in core
- Dependent: 75-99%, then 80-95%
- Dependent mass: 150-300 mg venlafaxine besylate in the core
Coating quantity gates
- Independent: coating is 3-25% of core weight
- Dependent: coating 5-15% (claim 12) and 5-25% (claim 17)
Polymer composition gates
- Independent: ammonio methacrylate copolymer included
- Dependent: copolymer is >=50% of coating
- Monomer-unit level: 7-14 mol%, then 8-12 mol%
- Type A/Type B balance:
- 65-100% A / 0-35% B (claim 7)
- 85-100% A / 0-15% B (claim 8)
- 70-100% A / 0-30% B (claim 17)
Excipients and architecture gates
- No extended release matrix excipients (claim 9)
- Or lipophilic matrix with co-processed excipient:
- Ca phosphate : fatty acid wax = 85:15 to 65:35
- excipient loading 10-20%
- lubricant 0.2-2%
Functional performance gate
- Dissolution thresholds in USP2 with SGF pH1.2 for 0-2 hours and SIF pH6.8 for 2-24 hours
- Time-point windows up to 24 hours >80%
What does this mean for potential design-arounds?
Primary ways to avoid claim coverage
A formulation can attempt to avoid infringement by missing one or more of the core claim dimensions:
- Core drug fraction below thresholds (dropping below 70% for claim 1, or outside 75-99% or 80-95% for dependent claims)
- Coating weight fraction outside 3-25% (claim 1) or outside 5-15% (claim 12) / 5-25% (claim 17)
- Polymer dominance failure
- coating not dominated by ammonio methacrylate copolymer component at >=50% of coating (claim 4 and downstream claims)
- Polymer composition shifts
- ammonio methacrylate units outside 7-14 mol% (or 8-12 mol%)
- Type A/Type B ratios outside specified windows
- ER architecture shifts
- “core free from extended release matrix excipients” (claim 9) avoids embodiments that do not use matrix excipients
- or conversely, uses an ER matrix framework that makes the “free from ER matrix excipients” limitation inapplicable
- Dissolution behavior outside Claim 19
- failing the specific USP2 time-point release windows under the pH-change dissolution protocol
Where copycat risk remains highest
Claim scope is narrow but still actionable for “near-identical” products because:
- It ties release to a standard-like dissolution apparatus (USP2) and explicit pH transition media.
- The coating and polymer constraints define the shell composition in a way that is difficult to substitute if the chosen polymer system already matches the ammonio methacrylate copolymer selection.
Patent landscape: what can be inferred from the claim set itself?
A complete US patent landscape analysis (family, continuations, priority chain, prosecution history, litigation status, ANDA/RLD/Orange Book listings, and relevant third-party patents) requires bibliographic and legal-status data. That data is not present in the prompt. Under the operating constraints, only what can be grounded directly in the provided claim language is addressed here.
What the claim language implies about the competitive technology lane
The technology lane is ER venlafaxine using:
- high-drug-load tablet cores
- ammonio methacrylate copolymer coating as the dominant release-modulating component
- release behavior tuned to stay low at 2 hours and then accelerate through 8-12 hours while reaching >80% by 24 hours
- optional lipophilic matrix embodiments using co-processed calcium phosphate and fatty acid wax
This suggests that competing formulations typically fall into one of two camps:
- coat-controlled ER using polymer-coated diffusion/erosion behavior
- matrix-controlled ER using lipophilic wax-based or calcium phosphate-wax co-processed excipients
US 7,776,358 spans both pathways through alternative dependent claim sets (claims 9-12 versus claims 13-17), but the polymer coat and dissolution profile remain central anchors.
Claim-by-claim scope map (actionable checklist)
| Claim |
What it adds beyond claim 1 |
Hard numeric limits |
| 1 |
ER coated tablet with defined core and coating |
core: >=70% venlafaxine besylate; coating: 3-25% of core weight; coating comprises ammonio methacrylate copolymer |
| 2 |
tighter core drug load |
75-99% |
| 3 |
tighter core drug load |
80-95% |
| 4 |
polymer dominance in coating |
copolymer >=50% of coating |
| 5 |
ammonio methacrylate unit level |
7-14 mol% |
| 6 |
tighter ammonio methacrylate unit level |
8-12 mol% |
| 7 |
polymer Type A/B mix |
65-100% Type A; 0-35% Type B |
| 8 |
tighter polymer Type A/B mix |
85-100% Type A; 0-15% Type B |
| 9 |
architecture restriction |
core free from extended release matrix excipients |
| 10 |
excipient optionality |
lubricant; optional filler sugars/MCC/calcium phosphate |
| 11 |
drug mass range |
150-300 mg venlafaxine besylate |
| 12 |
ties coating window and polymer blend |
coating 5-15%; copolymer >=50%; 85-100% Type A / 0-15% Type B |
| 13 |
adds matrix material |
matrix material present |
| 14 |
identifies matrix type |
lipophilic matrix material |
| 15 |
defines specific co-processed excipient ratio |
Ca phosphate : fatty acid wax = 85:15 to 65:35 |
| 16 |
defines excipient load and lubricant |
matrix excipient 10-20%; lubricant 0.2-2% |
| 17 |
ties coating amount and polymer blend to matrix embodiment |
coating 5-25%; copolymer >=50%; 70-100% Type A / 0-30% Type B |
| 19 |
enforces dissolution performance |
USP2, SGF pH1.2 0-2h then SIF pH6.8 2-24h; 2h <30%, 4h 30-55%, 8h 55-80%, 12h 65-90%, 24h >80% |
Key takeaways
- US 7,776,358 is composition-and-performance anchored: high venlafaxine besylate core loading (>=70% in claim 1), ammonio methacrylate copolymer-dominant coating (>=50% of coating in dependent claims) at defined coating weight fractions, and a specific USP2 dissolution profile with a pH transition.
- The most infringement-sensitive parameters are polymer specification and dissolution: ammonio methacrylate unit mol% (7-14; 8-12 in tighter claims), Type A/Type B ratios (including 85-100% A / 0-15% B), and the time-point release windows through 24 hours.
- The patent covers two ER architectures via claim alternatives: a “no ER matrix excipients” core path and a lipophilic matrix path using co-processed calcium phosphate and fatty acid wax, while still keeping the ammonio methacrylate coating central in dependent claims.
FAQs
1. What is the minimum venlafaxine besylate core fraction in claim 1?
At least 70% by claim language.
2. What coating weight fraction is permitted in the independent claim?
3% to 25% of tablet-core weight.
3. How is the ammonio methacrylate copolymer constrained in dependent claims?
It is >=50% of the coating and is further bounded by ammonio methacrylate unit mol% (7-14 or 8-12) and Type A/Type B composition (including 85-100% Type A / 0-15% Type B).
4. What dissolution target is required at 24 hours under claim 19?
>80% venlafaxine dissolved by 24 hours in USP2 under the SGF-to-SIF schedule.
5. Does the patent allow an ER matrix excipient-based formulation?
Yes, via claims 13-17, which add a lipophilic matrix with co-processed calcium phosphate and fatty acid wax at defined ratios and loadings.
References
[1] United States Patent 7,776,358. Claims 1-19 (as provided in the prompt).
